https://www.selleckchem.com/pr....oducts/bevacizumab.h
The Percepta genomic classifier has been clinically validated as a complement to bronchoscopy for lung nodule evaluation. The goal of this study was to examine the impact on clinical management decisions of the Percepta result in patients with low- and intermediate-risk lung nodules. A prospective "real world" registry was instituted across 35 US centers to observe physician management of pulmonary nodules following a nondiagnostic bronchoscopy. To assess the impact on management decisions of the Percepta genomic classifier, a subse
Like
Comment
Share